PBA
Paradigm Biocapital Advisors Portfolio holdings
AUM
$2.34B
This Quarter Return
+0.22%
1 Year Return
+13.3%
3 Year Return
+245.82%
5 Year Return
–
10 Year Return
–
AUM
$2.87B
AUM Growth
+$2.87B
(+0.58%)
Cap. Flow
+$202M
Cap. Flow
% of AUM
7.01%
Top 10 Holdings %
Top 10 Hldgs %
73.56%
Holding
35
New
4
Increased
20
Reduced
3
Closed
7
Top Buys
| 1 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$76.8M |
| 2 |
Vaxcyte
PCVX
|
$65.1M |
| 3 |
Janux Therapeutics
JANX
|
$59.7M |
| 4 |
Revolution Medicines
RVMD
|
$54.2M |
| 5 |
MoonLake Immunotherapeutics
MLTX
|
$45.5M |
Top Sells
| 1 |
Kura Oncology
KURA
|
$84.6M |
| 2 |
Arvinas
ARVN
|
$57.6M |
| 3 |
Immunovant
IMVT
|
$38.9M |
| 4 |
Cullinan Oncology
CGEM
|
$38.9M |
| 5 |
Merus
MRUS
|
$32.2M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Nuvalent
NUVL
$5.52B
| $420M | 14.61% | 5,363,379 +363,379 | +7% | +$28.4M |
|
2
Arcellx
ACLX
$3.85B
| $335M | 11.66% | 4,371,601 +371,601 | +9% | +$28.5M |
|
3
argenx
ARGX
$43.6B
| $296M | 10.3% | 481,305 +931 | +0.2% | +$573K |
|
|
4
Revolution Medicines
RVMD
$7.1B
| $287M | 9.97% | 6,553,111 +1,239,022 | +23% | +$54.2M |
|
|
5
Janux Therapeutics
JANX
$1.37B
| $188M | 6.55% | 3,515,986 +1,115,412 | +46% | +$59.7M |
|
6
Tarsus Pharmaceuticals
TARS
$2.47B
| $140M | 4.88% | 2,531,896 +91,451 | +4% | +$5.06M |
|
7
Edgewise Therapeutics
EWTX
$1.51B
| $120M | 4.17% | 4,493,929 +1,704,757 | +61% | +$45.5M |
|
|
8
Vaxcyte
PCVX
$4B
| $116M | 4.05% | 1,422,787 +795,055 | +127% | +$65.1M |
|
|
ONC
9
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $114M | 3.96% | 616,024 +415,688 | +207% | +$76.8M |
|
10
Crinetics Pharmaceuticals
CRNX
$2.92B
| $97.7M | 3.4% | 1,910,761 -605,925 | -24% | -$31M |
|
|
11
MoonLake Immunotherapeutics
MLTX
$3.54B
| $96M | 3.34% | 1,772,211 +840,731 | +90% | +$45.5M |
|
12
Disc Medicine
IRON
$2.07B
| $95M | 3.3% | 1,497,720 | – | – |
|
|
13
Merus
MRUS
$4.98B
| $71.1M | 2.47% | 1,689,922 -764,995 | -31% | -$32.2M |
|
14
Vera Therapeutics
VERA
$1.38B
| $60.8M | 2.11% | 1,437,339 +340,488 | +31% | +$14.4M |
|
15
Apogee Therapeutics
APGE
$2.17B
| $58.2M | 2.02% | 1,283,766 +581,949 | +83% | +$26.4M |
|
16
Olema Pharmaceuticals
OLMA
$375M
| $42.6M | 1.48% | 7,304,970 +1,801,370 | +33% | +$10.5M |
|
17
Pliant Therapeutics
PLRX
$101M
| $42.1M | 1.47% | 3,197,050 +92,564 | +3% | +$1.22M |
|
18
Immatics
IMTX
$619M
| $38.5M | 1.34% | 5,414,409 +1,509,547 | +39% | +$10.7M |
|
19
Cogent Biosciences
COGT
$1.69B
| $38.4M | 1.33% | 4,917,412 +307,650 | +7% | +$2.4M |
|
20
Spyre Therapeutics
SYRE
$996M
| $35.6M | 1.24% | 1,527,205 +259,624 | +20% | +$6.04M |
|
21
Viridian Therapeutics
VRDN
$1.5B
| $34.9M | 1.21% | 1,820,079 -1,075,610 | -37% | -$20.6M |
|
22
Y-mAbs Therapeutics
YMAB
$388M
| $33.2M | 1.15% | 4,236,346 +150,000 | +4% | +$1.17M |
|
23
Erasca
ERAS
$445M
| $27M | 0.94% | 10,752,354 +84,213 | +0.8% | +$211K |
|
|
TECX
24
Tectonic Therapeutic, Inc. Common Stock
TECX
$478M
| $22.4M | 0.78% | +485,105 | New | +$22.4M |
|
|
LENZ
25
LENZ Therapeutics
LENZ
$1.1B
| $22.2M | 0.77% | +770,455 | New | +$22.2M |
|